The Hemophilia Foundation of Greater Florida, a Chapter of the National Hemophilia Foundation, has been helping people with bleeding disorders since 1996. We have helped the bleeding disorders community improve their quality of life by offering programs and services to support healthier and more independent lives.
In November, the US Food and Drug Administration (FDA) approved simeprevir, a new oral drug, to treat the hepatitis C virus (HCV). Olysio, manufactured by Johnson & Johnson, is a protease inhibitor that halts the progression of HCV, preventing it from reproducing. The drug is used in combination with weekly injections of pegylated interferon (peg-IFN) and a daily ribavirin (RBV) oral pill.
In May 2011, the FDA approved the first protease inhibitors, Merck’s boceprevir (brand name Victrelis™) and Vertex Pharmaceutical’s telaprevir (brand name Incivek™). At the time, these two drugs represented the first new HCV therapies in ten years.
The Hemophilia Foundation of Greater Florida and the Florida Hemophilia Association are excited to announce the formation of the Bleeding Disorder Coalition of Florida, a collaborative advocacy group comprised of the two chapters, the state’s Hemophilia Treatment Centers and the bleeding disorders community at large.
The mission of the Bleeding Disorder Coalition of Florida is to preserve access to quality and affordable health care for all Floridians affected by bleeding disorders. In order to accomplish its mission, the Bleeding Disorder Coalition of Florida will educate necessary parties about bleeding disorders; develop and maintain relationships with key decisionmakers; cultivate relationships with organizations that have similar goals; inform consumers about its resources at all levels of government; and inform decisionmakers of the effects of legislation on persons with bleeding disorders and their families.
The New Year is finally here: 2014! Last year, HFGF gave Part I & Part II informative presentations of the Affordable Care Act in Tampa, Miami, Orlando, Gainesville, Jacksonville, and Fort Myers. Program speakers from Florida Blue and Health Insurance Brokers gave important information and provided immediate enrollment in the Marketplace, thereby avoiding enrollment problems that came about during the launch of the official WWW.healthcare.gov website.
The FDA and Triad Group, Inc., a manufacturer of over-the-counter alcohol swabs, have recalled lots of alcohol prep pads, alcohol swabs, and alcohol swabsticks that have private labels but are all manufactured by Triad Group, Inc. The products are marked as sterile and nonsterile. For a list of the third parties on the label, read the FDA release.